Introduction
Early randomized controlled clinical trials (RCTs) documented that cardiac resynchronization therapy (CRT) reduces morbidity 1 and improves survival 2 in heart failure (HF) patients with New York Heart Association (NYHA) class III-IV symptoms, QRS duration ≥120 ms and reduced ejection fraction (EF). More recently, CRT indication has expanded to less symptomatic patients since in HF. In particular, the first ESC guidelines (2005 and 2007) that addressed CRT recommended it for patients with NYHA class III-IV HF and QRS duration ≥120 ms 7, 12 whereas the most recent guidelines expand the recommendations to include also NYHA class II patients, but are more restrictive for narrower and non-LBBB QRS.
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Early studies, published before 2007, documented a prevalence of CRT indication between 5% and 10% in different patient cohorts 13, 14 whereas more recent studies of prevalence, reflecting modern clinical evidence, are scarce. 15, 16 Particularly, the effects of increasing evidence from RCTs and subsequent guideline updates on the prevalence of indication for CRT remain unknown.
Therefore, the main objective of the present study was to evaluate the prevalence of CRT indication in a large cohort of patients with HF and reduced EF, when recommendations from evolving clinical guidelines are considered.
Methods

Study protocol
Data in this study were derived from the Swedish Heart Failure Registry (SwedeHF), which has been described in detail elsewhere. 17 SwedeHF is a nationwide registry where 67 of 77 hospitals and 116 of approximately 1000 primary care outpatient clinics in Sweden report data on approximately 70 variables at discharge from hospital or at outpatient clinic visit. The inclusion criterion is clinically judged HF. Additional registry information, including the registration case report form, can be found online at www.swedeHF.se.
A multisite ethics committee has approved the establishment of the SwedeHF registry. In addition, this particular study also obtained separate ethics approval. Informed consent was not required or collected but all patients were informed about data entry into the registry and allowed to opt out. Figure 1 outlines patient selection in this study. In short, all 99 189 registrations between 11 May 2000 and 9 October 2014 were included in the analysis. Registrations were excluded in a hierarchical order if key data required for determining CRT indication were missing. However, the electrocardiogram (ECG) is not reported in patients with CRT, pacemakers or implantable cardioverter-defibrillators. Therefore, we did not exclude registrations where QRS duration or morphology was missing in patients with CRT. Subsequently, in cases where multiple registrations were present in the same patient, only the first registration was selected. The first registration was chosen to avoid survival bias, which is likely introduced if we were to choose the last registration. However, since some patients may have been implanted with CRT after the first registration, we performed a sensitivity analysis by documenting prevalence of CRT device and/or indication also at the time of last registration. Last, patients with EF ≥40% were excluded (in the registry, EF is reported as <30%, 30-39%, 40-49% and ≥50%).
Patient selection
If QRS duration ≤120 ms and LBBB were simultaneously reported, LBBB variable was changed to not present. To evaluate whether exclusion of missing data biased the study population, we compared the baseline characteristics of the selected study population, excluded patients (due to missing data) and the total population with EF <40% (study population and excluded patients). Table 1 lists the guidelines used in this study as well as the respective combinations of NYHA class, QRS duration and morphology and heart rhythm that warrant a recommendation for CRT indication. ESC guideline recommendations from 2005 and 2007 are identical and therefore analyzed as one (ESC 2005 (ESC /2007 . ESC adjudicates recommendations into four classes: class I ('is indicated'), class IIa ('should be considered'), class IIb ('may be considered') and class III ('is not recommended'). In this study, the primary analysis considers level of recommendations I to IIa since many will not consider a IIb recommendation sufficient for CRT indication (e.g. non-LBBB and QRS duration 120-149 ms). However, we performed a sensitivity analysis where class I-IIb was used to define indication (sensitivity analysis 1). Furthermore, EF is reported in the registry in categories (<30%, 30-39%, 40-49% and ≥50%) that does not perfectly match the cut-off for CRT indication (≤35%). In Sweden, EF is reported in increment of . 5-10% ranges and we defined EF criteria for CRT indication as ≤39% in the main analysis. However, since there may be patients in this cohort with actual EF 36-39% where CRT is not indicated, we performed a second sensitivity analysis where an EF <30% was required (sensitivity analysis 2). Furthermore, since the clinical effect of CRT in patients with atrial fibrillation (AF) is less evidence-based and controversial, we performed a third sensitivity analysis where sinus rhythm was a prerequisite for CRT indication (sensitivity analysis 3).
Definitions of guideline-recommended indication for cardiac resynchronization therapy
Data on ECG variables, such as QRS duration and morphology, are not recorded in SwedeHF in patients with CRT implanted. Therefore, indication was assumed in patients with CRT device present.
In this study, prevalence of a CRT indication was defined as: (number of patients with indication for CRT + number of patients with CRT)/total number of study patients. As a reference for electrical dyssynchrony in its broadest term, we determined also the prevalence of patients with QRS >130 ms and/or LBBB and/or CRT present.
CRT utilization was defined as percentage of the study population that had a CRT implanted.
In the study analysis we used registrations from 2000-2014. The registry had a run-in phase between 2000-2002 and only 1% of patients in the registry were registered in these years. Nevertheless, we included all patients (2000-2014) to enhance the power of this study. Since CRT documentation and implementation have evolved during this time period, we performed a fourth sensitivity analysis where CRT utilization was assessed only in registrations between 1 January 2010 and 9 October 2014 (sensitivity analysis 4). Table 2 details the baseline characteristics of the primary study population consisting of 17 193 patients with all data present to determine eligibility for CRT indication and EF ≤39%. CRT was present in 1171 patients resulting in a CRT utilization of 6.8%. According to sensitivity analysis 4 based only on registrations between 2010 and 2014, 600 of 8539 patients had CRT (7.0%). Also supporting underutilization of CRT after correction for time of registration in relation to publications of RCT and guideline recommendations, approximately 50% of patients in this study were registered in SwedeHF between 2010-2014, after publication of the RCTs and guidelines that expanded CRT indication to NYHA class II (see Supplementary material online, Table S1 ). When that last registration was selected instead of the first, the total prevalence of CRT indication remained unchanged but the prevalence of actual CRT implantation increased to 9.4%. Combining all patients as one cohort, NYHA class distribution was: 9% NYHA I, 45% NYHA II, 41% NYHA III and 5% NYHA IV. The distribution of QRS duration in the study population is shown in Figure 2 .
Results
Patient characteristics and prevalence of cardiac resynchronization therapy
Comparisons of the baseline characteristics between the selected study population, excluded patients (due to missing data) and all patients with EF ≤39% (study population + excluded patients) are shown in the Supplementary material online, Table  S2 . Owing to the large number of patients included, most variables were significantly different comparing the study population and excluded patients. However, the between-group differences were generally small in magnitude and of uncertain relevance. age 72 vs. 80 years) with lower proportion of females (28.0% vs. 40.6%) and higher coverage of HF-related drugs.
In the overall study population, 60% of the registrations were acquired after an outpatient visit and 40% at discharge after an hospitalization. Figure 3 shows the prevalence of CRT indication in 17 193 patients with EF ≤39% when different guidelines are considered (main analysis). The prevalence of CRT indication considering 2005/2007 ESC guidelines was 24.5%, which increased significantly to a peak prevalence of 30.0% (22.4% relative increase) when recommendations from the 2013 ESC guidelines were considered (P < 0.001). However, when the most recent set of guidelines was considered (ESC 2016), prevalence declined to 26.8% (10.7% relative decrease) (P < 0.001 vs. ESC 2013). This reduction in prevalence was mainly due to that 689 (13%) of the 5155 patients with indication for CRT according to the 2013 ESC guidelines, had a QRS duration <130 ms. Figure 4 shows the prevalence of CRT indication considering different ESC guidelines when applying sensitivity analysis 1 (class of recommendation I-IIa; Figure 4A ), 2 (EF <30% required; Figure 4B ), and 3 (sinus rhythm required; Figure 4C ). Overall, prevalence of CRT indication was slightly higher when class I-IIa, and lower when EF <30% and sinus rate was required. However, the changes in prevalence comparing the different guidelines were consistent in the three sensitivity analysis. The prevalence of QRS ≥130 ms and/or LBBB and/or presence of CRT was 37.5%.
Prevalence of cardiac resynchronization therapy indication when evolving guidelines are considered
Discussion
There are two main findings in this study. First, the prevalence of CRT indication increased significantly when recommendations from the 2013 ESC guidelines were used as determinant for CRT indication, compared to the 2005/2007 ESC guidelines. Subsequently, the prevalence declined significantly when the 2016 ESC guidelines were considered. Second, CRT utilization is lower than indicated, regardless of which guidelines are considered.
Expanding evidence and evolving guidelines and prevalence of cardiac resynchronization therapy indication
The first pivotal clinical studies of CRT in HF documented that resynchronization reduced morbidity 1 7, 12 Subsequently, evidence for expanding CRT indication was published between 2008-2010 as clinical trials proved CRT to be effective in reducing mortality and morbidity also in NYHA class II HF. 3 This expansion of trial-based evidence of CRT efficacy resulted in updates of the guidelines and NYHA class II was first declared a CRT indication in the 2010 ESC guidelines. On the other hand, subgroup analysis from the major trials has identified subgroups where CRT is less effective, and therefore may not be indicated. Most importantly, QRS morphology and duration play a role in therapy response. 2, 3 CRT is more effective in LBBB compared to right bundle branch block or unspecified QRS widening and its effectiveness increases with augmented QRS duration. Therefore, guidelines published after the 2005/2007 ESC guidelines apply stricter ECG criteria for CRT indication. In particular, the latest 2016 ESC guidelines considers QRS duration <130 ms a contraindication for CRT. In this study we demonstrate how the expanding evidence and guidelines have an impact on the prevalence of patients with CRT indication in a large cohort of HF patients. We document a significant increase in prevalence of CRT indication comparing the 2005/2007 (24.5%) and 2013 (30.0%) ESC guidelines. This increase was consistent in different sensitivity analyses. In this study, 45% of patients were in NYHA class II and 40% were in NYHA class III, which is consistent with the distribution of NYHA classes in the general SwedeHF population.
17 Therefore, expanding CRT indication from NYHA class III-IV to II-IV is likely to substantially impact the number of patients with indication and may explain the increased prevalence of CRT indication between 2005/2007 and 2013. Of patients without CRT but with QRS prolongation and/or LBBB in this study, 63% had LBBB morphology and 37% non-LBBB morphology. The overrepresentation of LBBB vs. non-LBBB morphology in HF patients with broad QRS complexes has also been documented in previous reports from SwedeHF 18 and is similar to that in some of the pivotal CRT trials. Taken together, this suggests that expansion to NYHA class II is the most important factor explaining the increase in indication for CRT, which was not outweighed by stricter QRS criteria in non-LBBB patients. Nevertheless, considering the latest guidelines with more stringent criteria for QRS duration, prevalence fell significantly by an absolute reduction of 3.2% and a relative reduction of 10.7%.
. With the exception of the RAFT trial, 3 clinical CRT studies have exclusively studied patients in sinus rhythm. Mainly due to the limited evidence for therapy efficacy in patients with AF (without His bundle ablation), NYHA class III-IV is still required for CRT indication. SwedeHF is an unselective nationwide registry and includes greater proportions of women and patients of higher age than trial cohorts. This may explain the high prevalence of AF in this study (43%) which is toward the higher end of the 10-50% range of AF prevalence in HF with reduced EF described in the literature. 19 In the present study the prevalence of CRT indication was reduced from 26.8% to 18.6% when patients with AF were excluded (considering the 2016 ESC guidelines). However, in spite of weak trial evidence, the European CRT survey showed that 22% of consecutive patients implanted with CRT at several European centres had AF as underlying rhythm. 20 Therefore, removing patients with AF from the estimated prevalence of CRT indication does not reflect either guideline recommendations or clinical practice in Europe. Instead, the abundance of AF and reduction in prevalence when patients with AF are omitted from the analysis in this study points out that further studies are warranted to document efficacy of CRT in patients with chronic AF.
Underutilization of cardiac resynchronization therapy
In this study the prevalence of CRT was 6.8% in patients with HF, whereas the prevalence of CRT indication in those without the device was consistently more than two to almost four times higher at 18-26% regardless of which guideline was considered. Also when adjusting for class I-IIa recommendations and applying a strict EF cut-off of <30% for CRT indication, there were twice as many patients without device but with indication compared to CRT recipients. In the primary analysis in this study we chose the first, rather than the last, registration of each patient. This was done to reduce the risk of introducing survival bias that would bias the study cohort to patients with less pronounced HF. A sensitivity analysis showed that by instead selecting the latest registration for each patient, the total prevalence of CRT indication remained unchanged but the prevalence of patients with actual CRT implanted increased modestly from 6.8% to 9.4%. This indicates that some patients actually received a CRT device after the first registration but it does not affect the main findings or conclusion of this study. Importantly, changes in guidelines do not necessarily and immediately translate into changes in clinical practice. This may affect the results regarding underutilization since we analyzed data from 2000-2014. However, in the sensitivity analysis where only data registered between 2010 and 2014 were considered, we still observed similar low utilization (7.0%) compared to when data from the whole study period were used (6.8%). This time period starts 5 years after the first pivotal clinical trial demonstrating mortality reduction with CRT and the first ESC guidelines were published. The data from this sensitivity analysis suggest that, although there may be a delay between publication of guideline recommendations and their implementation in clinical practice, such delay does not account for the low utilization rates in this study.
This finding is in line with several other studies documenting underutilization of CRT in patients with HF. 15, 16 Factors contributing to CRT underutilization are not fully understood but may include poor awareness of device therapy indication in the medical community and low referral rates. 21 Although CRT implantation has more than doubled in Sweden and Europe since 2004, implantation rate remains low in absolute numbers and the increase now seems to plateau out. 22 This seems unfortunate since we here report an increasing prevalence of CRT indication.
Limitations
This study has several limitations. The results describe the prevalence of CRT indication but we cannot adjust for contraindications to CRT (mainly expected survival <1 year), patients' reluctance toward therapy or clinical judgments against implantation. Therefore, the prevalence of indication for CRT described in this study may not accurately reflect suitable implantation numbers. Moreover, data on CRT utilization in this study represent a snap shot of patient status since only one registration per patient was included. It is possible that patients with a CRT indication but without device in this study were (i) implanted with CRT at a later time point, (ii) developed contraindication to CRT, and/or (iii) improved in terms of symptoms or EF so that CRT was no longer indicated. However, the magnitude of underutilization makes it unlikely that it would change even taking these factors under consideration. Also, background utilization of HF drugs was high ( Table 2) , which makes it less likely that significant reverse remodelling and/or symptom relief induced by enhanced pharmacological treatment would occur.
Since ECG variables are not recorded in patients with devices, we cannot assess the appropriateness of CRT implantation in patients with CRT, and correct indication was assumed. It is likely that some of these patients were implanted with CRT 'off-label'. This constitutes a limitation but it unlikely affects the main conclusions of this study.
Ejection fraction is registered in SwedeHF in categories that do not match the cut-off used as indication for CRT in clinical guidelines. Hence, some patients with EF 36-39%, where CRT is not indicated, are included in the main analysis of prevalence and underutilization, which therefore is likely somewhat exaggerated. However, the change in prevalence and a substantial underutilization was still present when a stricter EF criterion (<30%) was applied in sensitivity analysis 2.
QRS duration, NYHA class and EF are important factors when determining CRT indication. These variables are measured, or taken from patients' charts, and reported in the registry by individual physicians or nurses and the data are not adjudicated. Patients with chronic AF are required to have a well-controlled ventricular rate for CRT indication. In this study, the registry did not provide data on sequential heart rate measurements or Holter ECG data. Therefore, the prevalence of CRT indication in patients with AF may be slightly exaggerated. SwedeHF does not contain data on PQ interval or atrioventricular block. Therefore, we could not capture . patients with CRT indication due to a primary bradycardia indication for pacing, which has a class I recommendation in the most recent guidelines.
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Patients with missing data on variables required to determine CRT eligibility were excluded. This limits the generalizability of our findings. However, given the nationwide unselective coverage of SwedeHF, this included population is still more generalizable than that obtained from complete but selective data sets such as from clinical trials.
Conclusion
Among patients with HF and reduced EF, the prevalence of CRT indication increased significantly comparing recommendations from ESC guidelines published between 2005 and 2013, but then declined when the 2016 ESC guidelines were considered. The 2005-2013 increase may reflect the expansion of documented CRT efficacy to NYHA class II while the subsequent drop likely results from the more stringent criteria for QRS duration in the 2016 ESC guidelines. Actual CRT utilization is lower than indicated, regardless of which guidelines are considered.
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